Patients with locally advanced rectal cancer treated with FOLFOX before surgery had similar outcomes and side effect profiles to those treated with presurgical pelvic chemoradiation. Patients with ...
Sorafenib plus hepatic arterial infusion of oxaliplatin and fluorouracil vs sorafenib plus transarterial chemoembolization for advanced hepatocellular carcinoma: A biomolecular exploratory, randomized ...
In the phase 2 EDGE-Gastric trial (NCT05329766), the combination of monoclonal antibodies domvanalimab and zimberelimab ...
Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network In this randomized, open-label, multicenter ...
The authors say delivering FOLFOX via transarterial infusion could be a “perfect option for treating intrahepatic cholangiocarcinoma before patients receive targeted therapy, immunotherapy, or ...
“Metastatic colorectal cancer remains a formidable challenge with limited effective therapies. The promising early results with petosemtamab offer hope for advancing care and bringing new treatment ...
Medical experts review therapy options for metastatic colorectal cancer after FOLFOX/FOLFIRI, emphasizing regorafenib, FTD/TPI plus or minus bevacizumab, and fruquintinib due to the rarity of ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Omitting bolus 5 ...
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Dr Meyerhardt is ...
Six months of chemotherapy in low-risk stage 3 colorectal cancer patients increases neuropathy compared to three months. IDEA collaboration found similar survival outcomes between three and six months ...
Adding the drug cetuximab (brand name Erbitux) to standard chemotherapy after surgery for stage 3 colon cancer did not improve disease-free survival in patients, a new study concludes. Patients with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback